Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Censoring Survival Data01:09

Censoring Survival Data

629
Survival analysis is a statistical method used to analyze time-to-event data, often employed in fields such as medicine, engineering, and social sciences. One of the key challenges in survival analysis is dealing with incomplete data, a phenomenon known as "censoring." Censoring occurs when the event of interest (such as death, relapse, or system failure) has not occurred for some individuals by the end of the study period or is otherwise unobservable, and it might have many different...
629
Hazard Ratio01:12

Hazard Ratio

686
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
686
Introduction To Survival Analysis01:18

Introduction To Survival Analysis

924
Survival analysis is a statistical method used to study time-to-event data, where the "event" might represent outcomes like death, disease relapse, system failure, or recovery. A unique feature of survival data is censoring, which occurs when the event of interest has not been observed for some individuals during the study period. This requires specialized techniques to handle incomplete data effectively.
The primary goal of survival analysis is to estimate survival time—the time...
924
Assumptions of Survival Analysis01:15

Assumptions of Survival Analysis

478
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
478
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

520
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
520
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

692
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
692

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-World Outcomes of Elacestrant in ER+, HER2-, ESR1-Mutant Metastatic Breast Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same author

Challenges and Criteria for Single-Arm Trials Leading to an Added Benefit in German Health Technology Assessments.

PharmacoEconomics·2025
Same author

Letter to the Editor Regarding "Indirect Treatment Comparisons in Healthcare Decision Making: A Targeted Review of Regulatory Approval, Reimbursement, and Pricing Recommendations Globally for Oncology Drugs in 2021-2023".

Advances in therapy·2025
Same author

Assessing non-inferiority for binary matched-pairs data with missing values: a powerful and flexible GEE approach based on the risk difference.

BMC medical research methodology·2025
Same author

VISIT STROKE: non-inferiority of telemedicine-based neurological consultation for post-acute stroke patients - protocol of a prospective observational controlled multi-center study.

BMC health services research·2024
Same author

Questioning Conclusions and Statements on the German HTA System: A Critical Perspective.

Clinical pharmacology and therapeutics·2024
Same journal

Impact of Information Leakage in Platform Trials With Survival Endpoints on Type I Error Control.

Pharmaceutical statistics·2026
Same journal

Harmonic Fowlkes-Mallows Index for Medical Diagnostics Tests and Optimal Cut-Off Point Selection of Binary Diseases.

Pharmaceutical statistics·2026
Same journal

Early Phase Dose-Finding Designs for CAR-T Cell Therapies.

Pharmaceutical statistics·2026
Same journal

Optimizing Randomization Ratios in Clinical Trials With Survival Endpoints.

Pharmaceutical statistics·2026
Same journal

CUI-MET: A Clinical Utility Index Based Analysis and Decision Framework for Dose Optimization in Multiple-Dose, Multiple-Outcome Randomized Trials.

Pharmaceutical statistics·2026
Same journal

Will the Pharmaceutical Industry Need Statisticians in an AI World?

Pharmaceutical statistics·2026
See all related articles

Related Experiment Video

Updated: Mar 19, 2026

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

11.0K

Safety data from randomized controlled trials: applying models for recurrent events.

Johannes Hengelbrock1, Johanna Gillhaus2, Sebastian Kloss2

  • 1University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Pharmaceutical Statistics
|June 14, 2016
PubMed
Summary
This summary is machine-generated.

Recurrent event models like Andersen-Gill and Prentice-Williams-Peterson offer advanced analysis of adverse events in clinical trials, accounting for varying observation times and providing distinct treatment effect insights.

Keywords:
adverse eventsrandomized controlled trialsrecurrent eventssafety datasurvival analysis

More Related Videos

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.7K
Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

15.4K

Related Experiment Videos

Last Updated: Mar 19, 2026

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

11.0K
An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.7K
Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

15.4K

Area of Science:

  • Biostatistics
  • Clinical Trial Methodology
  • Pharmacovigilance

Background:

  • Traditional methods for reporting adverse events in randomized controlled trials (RCTs) using 2x2 tables do not account for differing observation times.
  • Standard survival analysis methods (Cox model, Kaplan-Meier) are limited to analyzing only the first safety-related event per subject.

Purpose of the Study:

  • To evaluate the applicability of recurrent event data models (Andersen-Gill and Prentice-Williams-Peterson) for analyzing safety data in RCTs.
  • To differentiate between direct treatment effects on event risk and total treatment effects considering event history.

Main Methods:

  • Discussion and application of the Andersen-Gill and Prentice-Williams-Peterson models for recurrent events.
  • Utilized simulated data to assess model performance across various scenarios.
  • Incorporated mean event frequency estimates to compare absolute event probabilities, especially with competing risks.

Main Results:

  • The Prentice-Williams-Peterson model estimates the direct treatment effect on event risk.
  • The Andersen-Gill model estimates the total treatment effect, including indirect effects via event history.
  • Simulations demonstrated the distinct performance of both models under different conditions.

Conclusions:

  • Recurrent event models provide a more comprehensive analysis of adverse events in RCTs than traditional methods.
  • The choice of model depends on whether a direct or total treatment effect is of primary interest.
  • Integrating mean event frequency analysis enhances the comparison of treatment effects on absolute event probabilities.